GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cara Therapeutics Inc
Shares of Cara Therapeutics, a biopharmaceutical company focused on treating itching, reflect its difficult journey. The chart is a history of clinical failures and dependence on a single drug, a prime example of binary risks in the biotech sector.
Share prices of companies in the market segment - Pharma kidney
Cara Therapeutics is a biotech company focused on the development and commercialization of new drugs for the treatment of pruritus associated with chronic kidney disease. We have classified it in the "Pharma Kidney" segment. The chart below reflects the dynamics of the niche of pharmaceutical companies focused on nephrology.
Broad Market Index - GURU.Markets
Cara Therapeutics is a biopharmaceutical company developing drugs to treat itching associated with chronic kidney disease and other conditions. As a component of the GURU.Markets index, it operates in a niche sector. The chart below represents the entire market. See how Cara shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
TVRD - Daily change in the company's share price Cara Therapeutics Inc
Change_co for Cara Therapeutics, a biopharmaceutical company, reflects the high volatility associated with drug development. Daily fluctuations indicate sensitivity to news about clinical trials for kidney disease treatments. This metric is a critical element for assessing binary risks in biotech on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma kidney
The biotech sector in which Cara Therapeutics Inc operates is highly dynamic. This chart reflects the industry's average volatility. It serves as a benchmark for assessing how sensitive Cara's kidney drug development business is to clinical trial news.
Daily change in the price of a broad market stock, index - GURU.Markets
Cara Therapeutics (parent company of TVRD) develops drugs to treat itching associated with chronic diseases. This is a highly specialized and risky niche in the pharmaceutical industry. The chart below shows the volatility in this sector, reflecting the high stakes associated with new drug development.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cara Therapeutics Inc
Cara Therapeutics' year-over-year performance is a story about the commercialization of its drug for the treatment of pruritus in dialysis patients. Its market capitalization change over the past 12 months reflects the drug's sales volume, as well as the results of clinical trials for its use in other conditions, which is key to expanding its potential market.
Annual dynamics of market capitalization of the market segment - Pharma kidney
Cara Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of pruritus. Its success hinges on the commercialization of its first approved drug. The chart below shows how its narrow focus, competitive environment, and efforts to expand its drug's applicability impact its volatile performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
The ticker symbol for Cara Therapeutics is CARA, not TVRD. Cara is a biotech company whose stock performance is entirely dependent on clinical trial results. Its chart isn't about economics, but about the binary outcomes of cutting-edge science and medicine, where one piece of news can change everything.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cara Therapeutics Inc
The value of Cara, a biopharmaceutical company, depends on its product cycle. The monthly fluctuations on the chart reflect sales data for its drug for treating itching in dialysis patients, as well as news about clinical trials aimed at expanding its use.
Monthly dynamics of market capitalization of the market segment - Pharma kidney
Cara Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the relief of pruritus. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess how its unique approach to treating chronic pruritus associated with kidney and skin diseases can address a significant unmet need.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cara Therapeutics is a biotech company whose value is tied to the success of its developments. The chart below shows that the company's monthly share price fluctuations are not correlated with overall market movements. Instead, they reflect investor expectations regarding clinical trial results and regulatory decisions.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cara Therapeutics Inc
Cara Therapeutics develops drugs to treat itching associated with chronic diseases. Its weekly stock price is volatile and depends entirely on clinical trial results and FDA decisions. The chart tells the story of the patient's quest for relief.
Weekly dynamics of market capitalization of the market segment - Pharma kidney
Cara Therapeutics, like the entire biotech sector, is extremely volatile. Weekly stock price fluctuations in this segment often reflect broader scientific breakthroughs or setbacks, which impact investor interest in the entire sector. The chart shows how the company is tracking this overall biotech trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cara Therapeutics is a biotech company whose stock moves in sync with clinical trial news. This chart is a great way to see how its weekly fluctuations are disconnected from overall market trends. Is the company living its own life, or is it being affected by the global sell-off?
Market capitalization of the company, segment and market as a whole
TVRD - Market capitalization of the company Cara Therapeutics Inc
Data on Cara Therapeutics (TVRD) may be inaccurate, as the company's ticker symbol is CARA. Cara Therapeutics's chart reflects the long and arduous development of a new painkiller. Its market capitalization reflects the market's reaction to clinical trial results and regulatory decisions.
TVRD - Share of the company's market capitalization Cara Therapeutics Inc within the market segment - Pharma kidney
Cara Therapeutics is a biopharmaceutical company whose market share is based on its focus on developing drugs to treat itching associated with chronic diseases. Its market capitalization reflects both its approved products and its research potential.
Market capitalization of the market segment - Pharma kidney
Cara Therapeutics is tackling chronic itching. How big is this problem? The chart below shows the overall market capitalization of the kidney-focused pharmaceutical sector. Its dynamics reflect the enormous need to treat symptoms that significantly impact quality of life but are often ignored.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Cara Therapeutics chart is a visualization of the complex development path of an anti-itch drug. Its market capitalization reflects both success in treating itching in dialysis patients and failures in other, broader indications. It's a diagram that illustrates the difficulty of expanding the use of a highly specialized drug.
Book value capitalization of the company, segment and market as a whole
TVRD - Book value capitalization of the company Cara Therapeutics Inc
For Cara Therapeutics, a biopharmaceutical company, book value is its material basis, consisting primarily of financial reserves for conducting clinical trials and commercializing its drugs. The chart below shows how this critical financial foundation has evolved.
TVRD - Share of the company's book capitalization Cara Therapeutics Inc within the market segment - Pharma kidney
Cara Therapeutics Inc. is a biopharmaceutical company whose tangible assets are research laboratories focused on developing treatments for itching associated with chronic diseases. The chart shows the share of this specialized R&D infrastructure within its therapeutic niche that the company controls.
Market segment balance sheet capitalization - Pharma kidney
Cara Therapeutics (TVRD, dubbed CARA) focuses on the treatment of itching. The graph shows its share of actual R&D assets. These are its laboratories where research is conducted, which forms the basis for the development of innovative non-narcotic analgesics.
Book value of all companies included in the broad market index - GURU.Markets
Cara Therapeutics' assets include laboratories and R&D centers where an innovative drug for treating itching in dialysis patients was developed. The chart shows how the company built its scientific and material capital to commercialize its discovery.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cara Therapeutics Inc
Cara Therapeutics' assets are its laboratories. Its market valuation is a bet on the commercial success of its drugs. The chart shows how investor expectations for sales and new developments have changed.
Market to book capitalization ratio in a market segment - Pharma kidney
Cara Therapeutics is a biopharmaceutical company focused on developing treatments for itching. Its valuation depends on the success of its lead drug. The chart shows how its market capitalization, based on expectations, relates to its assets.
Market to book capitalization ratio for the market as a whole
Cara Therapeutics is a biopharmaceutical company focused on developing treatments for itching associated with chronic diseases. Its valuation, compared to the average, is volatile and depends on the results of clinical trials and the commercial success of its first drug. This is a classic biotech story with high risks.
Debts of the company, segment and market as a whole
TVRD - Company debts Cara Therapeutics Inc
Cara Therapeutics, a biopharmaceutical company, is focused on developing drugs to treat pruritus associated with chronic diseases. This chart reflects its financial trajectory. Following failures in key trials, the company is managing its capital to advance its remaining programs, which requires strict financial discipline.
Market segment debts - Pharma kidney
Cara Therapeutics is a biotech company focused on developing treatments for itching associated with chronic diseases, particularly kidney disease. This chart shows how its leverage reflects the transition from development to commercialization of its first drug and the investments required to bring it to market and compete.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cara Therapeutics Inc
Cara Therapeutics is a biopharmaceutical company focused on developing drugs to treat pruritus associated with chronic diseases. This chart shows the company's reliance on debt to fund its clinical trials. It is an indicator of its financial risk during the long road to approval and commercial success.
Market segment debt to market segment book capitalization - Pharma kidney
Cara Therapeutics is a biopharmaceutical company focused on treating itching associated with chronic diseases. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to fund its clinical trials and the commercialization of drugs in this specific niche.
Debt to book value of all companies in the market
Cara Therapeutics (TVRD) is a biopharmaceutical company focused on developing treatments for itching associated with chronic diseases. Being in the clinical trials and commercialization stages, it requires significant capital. This chart of total market debt shows how easy it is for companies in this field to raise capital.
P/E of the company, segment and market as a whole
P/E - Cara Therapeutics Inc
Cara Therapeutics is a biotech company focused on developing treatments for itching associated with chronic diseases, particularly kidney disease. This chart reflects investor expectations for its lead drug, Korsuva. The dynamics are highly dependent on sales volume and success in expanding its use.
P/E of the market segment - Pharma kidney
Cara Therapeutics is a biopharmaceutical company focused on developing drugs to treat itching associated with chronic diseases, particularly kidney disease. This condition has few effective treatments. This chart shows the average valuation for the pharmaceutical sector, reflecting how investors value companies addressing unmet medical needs.
P/E of the market as a whole
Cara Therapeutics is a biopharmaceutical company developing drugs to treat itching associated with chronic diseases. Its valuation is entirely dependent on the success of its clinical trials and regulatory approval. Overall market sentiment, as reflected in this chart, is completely irrelevant.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cara Therapeutics Inc
Cara Therapeutics is a biopharmaceutical company focused on developing drugs to treat pruritus associated with chronic conditions, such as kidney disease. This graph reflects expectations for its niche but important market. The valuation is contingent on the commercial success of its approved drug and the results of trials of other candidates.
%20P%2FE%20Cara%20Therapeutics%20Inc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cara-Therapeutics-Inc&v=1772650418775 "Chart of the company's future (projected) P/E Cara Therapeutics Inc")
Future (projected) P/E of the market segment - Pharma kidney
Cara Therapeutics is a biopharmaceutical company focused on developing treatments for itching associated with chronic diseases, particularly kidney disease. This chart reflects expectations for its niche market. Comparing its profitability forecasts to the sector reveals how investors view its commercial potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-kidney&v=1772650418779 "Future (projected) P/E graph of the market segment - Pharma kidney")
Future (projected) P/E of the market as a whole
Cara Therapeutics is a biopharmaceutical company focused on developing treatments for itching associated with chronic diseases, such as kidney disease. This is a specific and underserved niche. This overall risk appetite curve influences the biotech sector's valuation, but for Cara, the success of its lead drug is key.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772650418781 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cara Therapeutics Inc
Cara Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of pruritus. Its financial results depend on the success of its lead drug. This graph shows the path from clinical trials to revenue generation, which is associated with high risks and costs associated with bringing a product to market.
Profit of companies in the market segment - Pharma kidney
Cara Therapeutics is a biopharmaceutical company focused on developing treatments for itching associated with chronic diseases, such as dialysis patients. This is a narrow but crucial niche. The revenue chart for the kidney pharmaceutical sector reflects how companies are identifying unmet medical needs and creating new markets for them.
Overall market profit
Cara Therapeutics is a biopharmaceutical company focused on developing new drugs for the treatment of itching associated with chronic diseases, particularly kidney disease. The company operates in a niche but important area, striving to improve patients' quality of life. Its success depends on the results of clinical trials and regulatory approval.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cara Therapeutics Inc
Cara Therapeutics develops drugs to treat itching associated with chronic diseases. This graph reflects the expected success of its lead drug. The company's profitability depends on sales volumes of this niche product and success in expanding its use.
%20profit%20of%20the%20company%20Cara%20Therapeutics%20Inc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cara-Therapeutics-Inc&v=1772650418818 "Graph of future (projected) profit of the company Cara Therapeutics Inc")
Future (predicted) profit of companies in the market segment - Pharma kidney
Cara Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for itching associated with chronic diseases. This chart reflects profitability forecasts for the biotech sector, providing insight into the company's potential as it targets an underserved but significant market.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-kidney&v=1772650418827 "Graph of future (predicted) profits of companies in a market segment - Pharma kidney")
Future (predicted) profit of the market as a whole
This chart illustrates expectations for a biopharmaceutical company. Cara Therapeutics' profit forecast hinges on the success of its drug for treating itching in dialysis patients. Expectations are based on the drug's commercial potential and the results of clinical trials in other areas.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772650418844 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cara Therapeutics Inc
Cara Therapeutics develops drugs to treat itching associated with chronic diseases. This chart shows its valuation, which is dependent on the commercial success of its first approved drug. The multiple reflects investor expectations regarding sales volumes and future potential.
P/S market segment - Pharma kidney
Cara Therapeutics is a biopharmaceutical company focused on developing treatments for pruritus associated with chronic kidney disease. Revenue is dependent on the commercial success of its products. This chart shows the average valuation in the sector, allowing one to assess how the market perceives Cara's potential to address this unmet medical need.
P/S of the market as a whole
Cara Therapeutics is a biopharmaceutical company specializing in the development of treatments for itching associated with chronic diseases, such as kidney disease. This graph, showing average revenue estimates for Cara Therapeutics, helps understand how the market views its niche specialization and the commercial potential of its drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cara Therapeutics Inc
Cara Therapeutics is a biotech company focused on developing treatments for itching associated with chronic diseases, particularly kidney disease. This chart reflects investor expectations regarding the commercial success of its lead drug, Korsuva, and the potential for expansion.
%20P%2FS%20Cara%20Therapeutics%20Inc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cara-Therapeutics-Inc&v=1772650418928 "The graph of the company's future (projected) P/S Cara Therapeutics Inc")
Future (projected) P/S of the market segment - Pharma kidney
Cara Therapeutics is a biopharmaceutical company focused on developing treatments for itching associated with chronic diseases. This chart compares market expectations for its future revenue with those of other companies working in the kidney treatment field. The valuation reflects investor opinion on the commercial potential of its drugs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-kidney&v=1772650418950 "Future (projected) P/S market segment graph - Pharma kidney")
Future (projected) P/S of the market as a whole
Cara Therapeutics is a biotech company specializing in the development of drugs to treat itching associated with chronic diseases. Its future depends on the success of its lead drug. The company's potential to address this unmet medical need is part of the overall progress in pharmaceuticals, as reflected in this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772650418956 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cara Therapeutics Inc
Cara Therapeutics is a biopharmaceutical company focused on developing treatments for pruritus associated with chronic kidney disease. This chart will reflect the revenue from sales of its approved drug, demonstrating the commercial potential of addressing this unmet medical need.
Sales of companies in the market segment - Pharma kidney
Cara Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing novel drugs for the treatment of pruritus associated with chronic kidney disease. Its approach targets peripheral nerve receptors. This chart shows overall sales in the pharmaceutical sector, illustrating how companies are identifying and addressing unmet medical needs.
Overall market sales
Cara Therapeutics is a biopharmaceutical company focused on developing treatments for pruritus associated with chronic diseases, such as kidney disease. This overall economic activity chart is important for Cara through the lens of funding and commercialization. A successful drug launch requires significant marketing efforts and support from the healthcare system.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cara Therapeutics Inc
Cara Therapeutics is a biopharmaceutical company focused on developing drugs to treat itching associated with chronic conditions such as kidney disease. This chart reflects analyst expectations for the commercial success of its approved drug and the potential of other developments in this underserved area of medicine.
%20sales%20of%20the%20company%20Cara%20Therapeutics%20Inc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cara-Therapeutics-Inc&v=1772650419107 "Schedule of future (projected) sales of the company Cara Therapeutics Inc")
Future (projected) sales of companies in the market segment - Pharma kidney
Cara Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for itching associated with chronic diseases. This chart shows projected revenues for the entire pharmaceutical sector. While it provides a general overview, for Cara, the key focus is on the commercial success of its first approved drug and the development of other programs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-kidney&v=1772650419145 "Schedule of future (projected) sales of companies in the market segment - Pharma kidney")
Future (projected) sales of the market as a whole
Cara Therapeutics is a biopharmaceutical company focused on developing treatments for itching associated with chronic diseases. Its success depends on the approval and commercialization of its drugs. This schedule, reflecting the state of the economy, influences overall healthcare costs, which determines how widely new drugs will be covered by insurance.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772650419153 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cara Therapeutics Inc
Cara Therapeutics is a biopharmaceutical company focused on treating itching associated with chronic diseases. This chart shows its transition from development to sales. Profitability now depends on the success of its drug with doctors and patients, and whether revenue can cover past and ongoing expenses.
Market segment marginality - Pharma kidney
Cara Therapeutics is a biopharmaceutical company specializing in the development of treatments for pruritus associated with chronic diseases. This chart depicts its operational structure at the commercialization stage of its first product. It allows for a comparison of how the company manages its marketing and research expenses compared to other biotech companies.
Market marginality as a whole
Cara Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel compounds targeting peripheral kappa opioid receptors. Its focus is on the treatment of pruritus associated with chronic diseases. The company's profitability depends on the success of its clinical programs. This total market return chart highlights Cara's commitment to addressing an unmet medical need.
Employees in the company, segment and market as a whole
Number of employees in the company Cara Therapeutics Inc
Cara Therapeutics is a biopharmaceutical company focused on developing treatments for itching associated with chronic diseases. This graph shows the team working on commercializing its first product. The staff dynamics reflect the transition from an R&D company to a commercial organization.
Share of the company's employees Cara Therapeutics Inc within the market segment - Pharma kidney
This indicator reflects the scientific focus of Cara Therapeutics. The company's pharmaceutical sector is focused on developing drugs targeting peripheral kappa opioid receptors for the treatment of pruritus. This team of scientists is striving to create a non-narcotic analgesic and antipruritic agent free of the side effects of traditional opioids.
Number of employees in the market segment - Pharma kidney
Cara Therapeutics is a biopharmaceutical company focused on developing drugs to treat itching associated with chronic diseases (such as kidney disease). It's an under-recognized but serious medical problem. This chart shows how the pharmaceutical industry is seeking solutions to improve patients' quality of life, creating jobs for scientists in highly specialized fields.
Number of employees in the market as a whole
Cara Therapeutics, Inc. is a biotech company focused on the treatment of itching. Its success depends on the results of clinical trials. This general employment schedule is not relevant to its operations, as the need for relief from chronic itching is not dependent on the state of the economy.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cara Therapeutics Inc (TVRD)
Cara Therapeutics is a biotech company focused on developing drugs to treat itching. This chart reflects the risks and expectations in biotech. The metric's dynamics are highly dependent on clinical trial results. A high PE value indicates investors' confidence in the potential of its lead drug, rather than in its current revenue.
%20of%20the%20company%20Cara%20Therapeutics%20Inc%20(TVRD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cara-Therapeutics-Inc-TVRD&v=1772650419382 "Chart of market capitalization per employee (in thousands of dollars) of the company Cara Therapeutics Inc (TVRD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma kidney
Cara Therapeutics Inc (TVRD) is developing drugs to treat itching associated with chronic kidney disease. For a single-focused biotech, this metric reflects the market potential of its lead candidate. The chart shows investors' assessment of the drug's future success.
%20by%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-kidney&v=1772650419410 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma kidney")
Market capitalization per employee (in thousands of dollars) for the overall market
Cara Therapeutics Inc. is a biotech company developing drugs to treat itching associated with chronic diseases. This chart reflects investor valuations of its niche R&D program. The high cost per employee reflects a bet that its drugs will successfully complete clinical trials and find their niche in the market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772650419427 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cara Therapeutics Inc (TVRD)
Cara Therapeutics (TVRD) is a biotech company focused on treating pruritus in patients with kidney failure. They have an approved drug (Korsuva). This chart shows the commercial success of this niche drug. Earnings per employee depend on how quickly it becomes a standard of care for dialysis patients.
%20Chart%20Cara%20Therapeutics%20Inc%20(TVRD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cara-Therapeutics-Inc-TVRD&v=1772650419457 "Company Profit Per Employee (in thousands of dollars) Chart Cara Therapeutics Inc (TVRD)")
Profit per employee (in thousands of dollars) in the market segment - Pharma kidney
Cara Therapeutics (TVRD) is a biotech company focused on developing treatments for pruritus associated with chronic diseases (e.g., kidney disease). This chart shows how effectively the company is commercializing its approved drug, KORSUVA. It serves as a benchmark for assessing the success of this highly targeted drug launch.
%20in%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-kidney&v=1772650419468 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma kidney")
Profit per employee (in thousands of dollars) for the market as a whole
Cara Therapeutics (TVRD) (ticker symbol CARA) is a biopharmaceutical company focused on treating pruritus associated with chronic diseases (e.g., kidney disease). This chart reflects their commercial trajectory. They have an approved drug. This metric shows how well sales revenue covers ongoing R&D and marketing expenses.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772650419478 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cara Therapeutics Inc (TVRD)
Cara Therapeutics is a biopharmaceutical company specializing in the development of treatments for pruritus. This chart reflects the company's activity in the commercialization stage. Revenue per employee growth is dependent on the success of its first approved drug.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cara-Therapeutics-Inc-TVRD&v=1772650419496 "Sales chart per company employee Cara Therapeutics Inc (TVRD)")
Sales per employee in the market segment - Pharma kidney
Cara Therapeutics (TVRD) is a biotech company specializing in the treatment of pruritus associated with chronic diseases (e.g., kidney disease). This chart shows the average revenue per employee in the segment. It serves as a comparison to a sector where productivity depends on successful R&D and commercialization.
Sales per employee for the market as a whole
Cara Therapeutics is a biotech company specializing in the treatment of itching associated with chronic diseases (such as kidney failure). They have an approved drug. This metric reflects how their focused team (R&D, sales) generates revenue from this very niche but important drug.
Short shares by company, segment and market as a whole
Shares shorted by company Cara Therapeutics Inc (TVRD)
Cara Therapeutics (TVRD) is a biotech company focused on treating pruritus associated with kidney disease. The bearish sentiment seen in this chart reflects the commercial failure of its drug, Korsuva. The bears are betting that demand for the drug has fallen far short of expectations, and the company is burning through cash.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cara-Therapeutics-Inc-TVRD&v=1772650419551 "Short Shares Chart for the Company Cara Therapeutics Inc (TVRD)")
Shares shorted by market segment - Pharma kidney
Cara Therapeutics (TVRD) is a biotech company focused on treating pruritus, particularly in dialysis patients (Korsuva). This chart shows the overall sentiment in the sector, reflecting investor concerns about the drug's commercial failure or the difficulty of treating such a specific symptom.
Shares shorted by the overall market
Cara Therapeutics (TVRD) is a biotech company focused on treating chronic pruritus. It's a complex market with mixed trial results. This chart shows the overall level of fear. When it rises, investors are reluctant to take risks on companies with unclear commercial prospects, like TVRD.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cara Therapeutics Inc (TVRD)
Cara Therapeutics is a biotech focused on treating pruritus associated with kidney disease. The company suffered a major trial failure. This chart measures how investors react to the "afterlife." It shows when the stock is "oversold" due to desperation or "overbought" due to speculative hopes for remaining R&D.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cara-Therapeutics-Inc-TVRD&v=1772650419614 "RSI 14 indicator chart for the company's stock Cara Therapeutics Inc (TVRD)")
RSI 14 Market Segment - Pharma kidney
Cara Therapeutics is a biopharmaceutical company focused on treating chronic itching associated with kidney disease. Their lead drug, Korsuva (diphelikephalin), targets this debilitating condition. This chart reflects the overall sentiment in the biotech sector, helping to gauge how the market views this speculative industry.
RSI 14 for the overall market
Cara Therapeutics (TVRD) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TVRD (Cara Therapeutics Inc)
Cara Therapeutics (TVRD) is a biotech company focused on treating pruritus associated with chronic kidney disease. This chart shows the average 12-month forecast. It reflects analyst expectations for the approved drug Korsuva's sales and market potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TVRD-Cara-Therapeutics-Inc&v=1772650419637 "A chart showing analyst consensus forecasts for the expected stock price. TVRD (Cara Therapeutics Inc)")
The difference between the consensus estimate and the actual stock price TVRD (Cara Therapeutics Inc)
Cara Therapeutics (TVRD - *Note: Ticker is TVRD, Name is Cara*) is a biotech focused on pain and itch. Its key product is Korsuva, a unique drug that targets itch associated with kidney disease (in dialysis patients). This chart shows the difference between the consensus estimate and the price. It reflects analyst confidence in Korsuva's commercial success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TVRD-Cara-Therapeutics-Inc&v=1772650419656 "A chart showing the difference between the consensus forecast and the actual stock price. TVRD (Cara Therapeutics Inc)")
Analyst consensus forecast for stock prices by market segment - Pharma kidney
Cara Therapeutics (TVRD) is a biopharmaceutical company focused on the treatment of pruritus. Its drug Korsuva is approved for dialysis patients. This chart shows general expectations for the kidney pharmaceutical sector. It reflects whether experts believe the anti-pruritus market has the potential to expand.
Analysts' consensus forecast for the overall market share price
Cara Therapeutics is a biotech company focused on treating pruritus associated with chronic diseases (e.g., kidney failure). This chart shows overall market sentiment. For Cara, as an R&D company, it's important to understand how overall risk appetite (sentiment) influences the funding and commercialization of their niche drug. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cara Therapeutics Inc
Cara Therapeutics is a biotech company focused on pruritus. Their lead drug (Korsuva/Kapruvia) is a therapy for the treatment of dialysis-associated pruritus (CKD-aP). This chart is a barometer of their launch. It likely reflects the growth rate of their drug for dialysis patients and their R&D efforts to expand its use to other types of pruritus.
AKIMA Market Segment Index - Pharma kidney
Cara Therapeutics (TVRD) is a single-product biotech focused on treating chronic itching; after a string of failures, the company is commercializing its drug (Korsuva) for the treatment of itching in dialysis patients. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this niche (itch) R&D model (TVRD) differentiate it from the average pharma company?
The AKIM Index for the overall market
Cara Therapeutics is a commercial-stage biopharmaceutical company focused on the treatment of chronic pruritus. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which faces market challenges during drug introduction, compares to overall economic trends.
